The Dermatology Digest

AUGUST 13, 2024

More data will be needed to define the safety profile of JAK inhibitors in Down syndrome, and we look forward to the completion of the trial and analysis of the full dataset.”

Clinic 74

Clinic Safety Dermatitis Medical 74

The Dermatology Digest

MARCH 18, 2024

If approved, we believe that DFD-29 will be the only oral medication to address both inflammatory lesions and erythema from rosacea, and will be a preferred treatment option by physicians and their patients to address the condition.”

Rosacea 74

Rosacea Medical Clinic Office 74

The Dermatology Digest

SEPTEMBER 12, 2024

“The positive pivotal data from this study reinforce the potential of Dupixent to offer a new treatment option for the many people suffering from chronic spontaneous urticaria who do not respond to standard-of-care antihistamines,” says Dietmar Berger, MD, PhD, Chief Medical Officer, Global Head of Development at Sanofi, in a news release.

Safety 36

Safety Office Dermatology Medical 36

The Dermatology Digest

FEBRUARY 14, 2024

“We are thankful to the patients and medical experts whose insights informed our clinical trials, which assessed nemolizumab’s ability to reduce the symptoms of itch and skin lesions. In the ARCADIA program, nemolizumab clinically improved skin lesions and rapidly improved itch and sleep disturbance.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

FEBRUARY 11, 2024

A meta-analysis of 45 randomized clinical trials comprised of 12,996 patients disclosed neither an increased risk of major cardiovascular events (MACE) such as heart attack and stroke) nor of venous thromboembolic events (VTE). This particular study did not address other safety concerns, such as all-cause mortality, infections, or cancer.

Safety 74

Safety Dermatology Clinic Therapy 74

New Age Spa Institute

APRIL 18, 2024

In the field of medical aesthetics, lasers are used primarily for hair removal, promoting the destruction of hair follicles and sealing off the vessels that feed hair bulbs. LASER treatments are classified as medical procedures due to their invasive nature and the specific training required to operate these powerful devices.

Legal 52

Legal Hair Removal Safety Esthetician 52

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. Ch’en, a medical student at the Albert Einstein College of Medicine in the Bronx, New York, and Peter A.

Treatments 77

Treatments Dermatitis Therapy Safety 77

The Dermatology Digest

JUNE 12, 2024

The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals. Evolus, Inc. is rolling out Nuceiva (botulinum toxin type A) across Spain. Nuceiva is licensed in the United States under the brand name Jeuveau. Side effects were similar to others in this class of medicine.

Safety 36

Safety Branding Facials Clinic 36

The Dermatology Digest

FEBRUARY 8, 2024

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 104

Retinol Social Media Skincare Routine Skincare 104

US Dermatologt Partners

JUNE 1, 2024

These medications have been staples in psoriasis management, particularly in countries like Germany, where they are frequently prescribed for moderate to severe cases. A study involving 245 patients showed significant improvements at 16 weeks, confirming its efficacy and safety in younger populations.6

Therapy 41

Therapy Injections Safety Management 41

The Dermatology Digest

AUGUST 14, 2024

s VP-315 is showing promise in the treatment of basal cell carcinoma, according to Part 2 of its Phase 2 clinical trial. Patients may be cured with simple injections of VP-315,” adds Jonathan Kantor, MD, a dermatologist and Mohs surgeon at Florida Center for Dermatology, which was the leading enrollment site for the clinical study.

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

The Dermatology Digest

FEBRUARY 22, 2024

DermBiont has completed enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% We are pleased to have completed enrollment in our CT-213 clinical trial evaluating SM-020 gel 1.0% for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D.,

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

DermBiont has completed enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% We are pleased to have completed enrollment in our CT-213 clinical trial evaluating SM-020 gel 1.0% for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D.,

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

AUGUST 13, 2024

FDA The approval is based on positive results from the phase III OLYMPIA clinical trials – the largest clinical trial program conducted in this condition to date – in which nemolizumab demonstrated significant and clinically meaningful improvements in itch and skin nodules at Week 16, with rapid reductions in itch observed as early as Week 4.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

MARCH 5, 2024

Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the second half of 2024. .: Botox Cosmetic (Allergan), Dysport (Galderma), Jeuveau (Evolus), Xeomin (Merz Aesthetic), Daxxify (Revance), and Letybo (Hugel). and Europe.

Branding 74

Branding Injections Safety Facials 74

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

AUGUST 15, 2024

All nine treated BCCs (1 superficial, 4 nodular, and 4 infiltrating) across seven enrolled subjects to date showed “prompt, visible, and robust” tumor responses during treatment with SM-020 1% twice daily for 28 days, resulting in partial or total reduction of clinically visible tumor.

Clinic 36

Clinic Scarring Office Safety 36

The Dermatology Digest

FEBRUARY 27, 2024

. “The approval of SIMLANDI marks the first high-concentration, citrate-free biosimilar to Humira with IC status,” says Dr. Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

AAAMS

JULY 17, 2023

Ethics are crucial in the medical field because they help protect patients and medical practices. Ethical doctors prioritize their patients’ best interests to maintain health and safety. Compared to traditional medical practices, aesthetic medicine presents unique ethical challenges.

Ethics 52

Ethics Surgery Safety Legal 52

Kim Gallo Esthetics

FEBRUARY 27, 2024

From futuristic at-home devices to clinics equipped with state-of-the-art machinery, technology has placed the tools for radiant skin in the hands of the many. The accessibility of tools and treatments prompts questions about their efficacy and safety, reminding us to trust professionals for guidance and comprehensive understanding.

Skincare 314

Skincare Esthetician Skincare Routine Chemical Peels 314

The Dermatology Digest

FEBRUARY 7, 2024

The total duration of the trial was up to 24 weeks, which included a four-week screening period, a 16-week treatment period and a four-week safety follow-up period. Lower levels of hBD-2 were observed with clinical response and indicate inhibition of the IL-17/IL-23 axis. and Janssen Biotech, Inc.

Safety 36

Safety Clinic Office Dermatology 36

NIMA Institute

JUNE 30, 2023

In the fast-paced world of medical esthetics, staying at the forefront of the industry is crucial to success. If you’re looking to expand your skill set and advance your career in medical esthetics, Nima offers comprehensive Botox and filler training that can elevate your expertise to new heights.

Training 52

Training Medical Esthetics Ethics Esthetics 52

The Dermatology Digest

MARCH 10, 2024

55% of people experienced clinically meaningful itch relief ( Peak Pruritus Numerical Rating Scale ≥4-point improvement) §. No new safety signals were observed and there were no serious adverse events reported. Lilly plans to share full efficacy and safety results from the study at future congresses.

Skin Types 36

Skin Types Fitzpatrick Scale Dermatitis Safety 36

The Dermatology Digest

MAY 8, 2024

The safety profile of subcutaneous nivolumab was consistent with the IV formulation. The pharmacokinetics, efficacy, and safety results from CheckMate -67T were presented at the American Society of Clinical Oncology (ASCO) 2024 Genitourinary Cancers Symposium. “An

Safety 36

Safety Therapy Dermatology Injections 36

The Dermatology Digest

JUNE 20, 2024

The FDA approval was supported by results from the two pivotal Phase 3 ‘CARDIGAN’ studies which evaluated the efficacy and safety of Sofdra versus vehicle and enrolled 701 patients with primary axillary hyperhidrosis. Vince Ippolito. “As

Safety 36

Safety Dermatology Clinic Medical 36

The Dermatology Digest

MARCH 5, 2024

Additionally, more than 85% of clinical trial subjects were satisfied with how balanced, well-proportioned, and symmetric their face looked three months after treatment. The Allergan Medical Institute (AMI) team can train aesthetic providers on safe and effective treatments using the Allergan Aesthetics portfolio to address 90% of the face.

Portfolios 74

Portfolios Injections Training Facials 74

The Dermatology Digest

JANUARY 14, 2024

The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. We are pleased to be able to share these individual response data with the wider dermatology community, and develop a better understanding about the broad range of clinical responses for roflumilast cream in this condition.”

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

AAAMS

MARCH 26, 2024

Botox and dermal fillers are powerful treatments for a wide range of aesthetic and medical conditions, but they require precise application from skilled and certified professionals. Licensed medical professionals can only purchase this controlled substance through pharmaceutical supply chains. Can Aestheticians Administer Botox?

Injections 52

Injections Chemical Peels Training Surgery 52

The Dermatology Digest

APRIL 23, 2024

Health departments and health care providers can contact the CDC clinical botulism service 24/7 at 770- 488-7100. If public health clinical consultation supports botulism, request antitoxin and begin treatment as soon as it is available. Clinician reporting A suspected case of botulism is a clinical and public health emergency.

Injections 36

Injections Hospital Clinic Consultations 36

The Dermatology Digest

JANUARY 14, 2024

The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. People with seborrheic dermatitis who don’t use topical steroids are 3.5 Zoryve foam; 48.3%

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

FEBRUARY 12, 2024

The results were highly statistically significant and clinically meaningful.” “There is a significant medical need here with very limited approved treatment options available. Secondary endpoints include change from baseline for itch and hives severity scores, and safety. 23-26,2024.

Hospital 45

Hospital Safety Clinic Dermatology 45

The Dermatology Digest

MAY 31, 2024

The Company states that STS-01 “builds on a mechanism with a well established safety profile in dermatology, and existing evidence of efficacy in this indication through targeting key relevant cytokines. ” Complete study results are expected to be presented at a future medical meeting.

Hospital 36

Hospital Safety Dermatology Clinic 36

Southeastern Esthetics Institute

AUGUST 23, 2016

Estheticians and consumers alike understand the advanced changes that can be made within a medical setting - and physicians are realizing the supportive role that Estheticians can bring to their practices. Working in a medical setting as an Esthetician can be both rewarding and beneficial for both yourself and your clients alike.

Esthetician 195

Esthetician Esthetics Document Office 195

Aesthetic Advancements Institute (AAI)

JUNE 20, 2023

As with any new aesthetic treatment, it is important for medical professionals to understand the product and its proper application in order to ensure safe and effective results. By having a comprehensive understanding of facial anatomy, medical professionals can ensure the safety of their patients and increase their satisfaction rate.

Facials 36

Facials Training Injections Safety 36

The Dermatology Digest

AUGUST 28, 2024

With its unique mechanism of action and compelling early efficacy data, I am excited by the potential for KB301 to change the treatment paradigm in the field of medical aesthetics and meet the growing demand for treatments that fundamentally replenish the skin or delay signs of aging.”

Wrinkles 36

Wrinkles Injections Collagen Hydration 36

The Dermatology Digest

DECEMBER 15, 2023

“This is a once-daily non-steroidal treatment that doesn’t have any duration on use,” Patrick Burnett, MD, PhD, chief medical officer at Arcutis, tells TDD. Seborrheic dermatitis is not a “by-the-way diagnosis,” says Neal Bhatia, MD, Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego, CA.

Dermatitis 36

Dermatitis Safety Clinic Medical 36